Skip to main content

Advertisement

Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis

Fig. 4

Forest plot of the meta-analysis showed a significant decrease in the numbers of monthly migraine days after therapy with CGRP-mAbs compared with placebo from baseline to weeks 1–4, 5–8, and 9–12. a The numbers of monthly migraine days of CGRP-mAbs and placebo at weeks 1–4; b The numbers of monthly migraine days of CGRP-mAbs and placebo at weeks 5–8; c The numbers of monthly migraine days of CGRP-mAbs and placebo at weeks 9–12. CGRP-mAbs, monoclonal antibodies to CGRP and its receptor; IV, inverse variance; CI, confidence interval

Back to article page